Symbol="LYEL"
AssetType="Common Stock"
Name="Lyell Immunopharma Inc"
Description="Lyell Immunopharma, Inc., a T-cell reprogramming company, is dedicated to the development of T-cell therapies for patients with solid tumors. The company is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington."
CIK="1806952"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="576597000"
EBITDA="-162159008"
PERatio="None"
PEGRatio="None"
BookValue="3.339"
DividendPerShare="0"
DividendYield="0"
EPS="-0.68"
RevenuePerShareTTM="0.343"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.116"
ReturnOnEquityTTM="-0.218"
RevenueTTM="84195000"
GrossProfitTTM="84683000"
DilutedEPSTTM="-0.68"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.882"
AnalystTargetPrice="7.25"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="20.91"
PriceToBookRatio="1.066"
EVToRevenue="7.42"
EVToEBITDA="-1.436"
Beta="-1.432"
num_52WeekHigh="8.74"
num_52WeekLow="1.77"
num_50DayMovingAverage="3.047"
num_200DayMovingAverage="3.131"
SharesOutstanding="249609000"
DividendDate="None"
ExDividendDate="None"
symbol="LYEL"
open="2.28"
high="2.37"
low="2.26"
price="2.31"
volume="709126.00"
latest_trading_day="2023-08-11"
previous_close="2.31"
change="0.00"
change_percent="0.0000%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="43"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="57"
Volume_recent_avg="1024102"
Change_recent_avg="0.01"
Delta_recent_avg="0.24"
Variance_recent_avg="0.12"
Change_ratio_recent_avg="-0.22"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="57"
Aroon_momentum_negative="43"
image_negative_thumbnail_id_1="1113"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0146.jpeg"
image_negative_thumbnail_id_2="1127"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0160.jpeg"
image_neutral_thumbnail_id_1="579"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0020.jpeg"
image_neutral_thumbnail_id_2="565"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0034.jpeg"
image_positive_thumbnail_id_1="1001"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0163.jpeg"
image_positive_thumbnail_id_2="678"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0030.jpeg"
image_professor_thumbnail_id_1="1189"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0023.jpeg"
image_professor_thumbnail_id_2="1177"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0011.jpeg"
